Curis (CRIS) Competitors $1.73 -0.10 (-5.46%) As of 03:17 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CRIS vs. DOMH, FBIO, SABS, BOLT, AMGN, GILD, VRTX, REGN, ALNY, and BIIBShould you be buying Curis stock or one of its competitors? The main competitors of Curis include Dominari (DOMH), Fortress Biotech (FBIO), SAB Biotherapeutics (SABS), Bolt Biotherapeutics (BOLT), Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Alnylam Pharmaceuticals (ALNY), and Biogen (BIIB). These companies are all part of the "biotechnology" industry. Curis vs. Its Competitors Dominari Fortress Biotech SAB Biotherapeutics Bolt Biotherapeutics Amgen Gilead Sciences Vertex Pharmaceuticals Regeneron Pharmaceuticals Alnylam Pharmaceuticals Biogen Dominari (NASDAQ:DOMH) and Curis (NASDAQ:CRIS) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, valuation, media sentiment, analyst recommendations, dividends and profitability. Does the media favor DOMH or CRIS? In the previous week, Dominari had 3 more articles in the media than Curis. MarketBeat recorded 6 mentions for Dominari and 3 mentions for Curis. Curis' average media sentiment score of 1.03 beat Dominari's score of 0.01 indicating that Curis is being referred to more favorably in the news media. Company Overall Sentiment Dominari Neutral Curis Positive Do institutionals & insiders believe in DOMH or CRIS? 42.5% of Dominari shares are held by institutional investors. Comparatively, 30.0% of Curis shares are held by institutional investors. 33.0% of Dominari shares are held by company insiders. Comparatively, 5.7% of Curis shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Is DOMH or CRIS more profitable? Dominari has a net margin of -36.01% compared to Curis' net margin of -341.24%. Curis' return on equity of 0.00% beat Dominari's return on equity.Company Net Margins Return on Equity Return on Assets Dominari-36.01% -94.32% -78.21% Curis -341.24%N/A -102.22% Which has better valuation & earnings, DOMH or CRIS? Dominari has higher revenue and earnings than Curis. Dominari is trading at a lower price-to-earnings ratio than Curis, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDominari$18.15M5.60-$14.70M-$2.37-2.79Curis$10.91M1.98-$43.39M-$4.88-0.35 Do analysts rate DOMH or CRIS? Curis has a consensus target price of $17.00, suggesting a potential upside of 882.66%. Given Curis' stronger consensus rating and higher possible upside, analysts clearly believe Curis is more favorable than Dominari.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dominari 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Curis 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more volatility and risk, DOMH or CRIS? Dominari has a beta of 0.5, meaning that its stock price is 50% less volatile than the S&P 500. Comparatively, Curis has a beta of 3.66, meaning that its stock price is 266% more volatile than the S&P 500. SummaryDominari beats Curis on 9 of the 16 factors compared between the two stocks. Get Curis News Delivered to You Automatically Sign up to receive the latest news and ratings for CRIS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CRIS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CRIS vs. The Competition Export to ExcelMetricCurisMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$21.88M$3.13B$5.71B$9.79BDividend YieldN/A2.21%3.77%4.10%P/E Ratio-0.3620.9230.9125.28Price / Sales1.98232.70404.2188.50Price / CashN/A41.5625.2228.45Price / Book-2.449.779.536.01Net Income-$43.39M-$54.74M$3.26B$265.34M7 Day Performance6.13%8.37%4.66%2.89%1 Month Performance-3.89%7.94%5.35%1.61%1 Year Performance-58.61%18.27%32.14%25.61% Curis Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CRISCuris3.2217 of 5 stars$1.73-5.5%$17.00+882.7%-56.2%$21.88M$10.91M-0.3660DOMHDominari0.6596 of 5 stars$5.33-7.0%N/A+305.1%$83.91M$18.15M-1.184News CoverageEarnings ReportAnalyst UpgradeFBIOFortress Biotech2.3698 of 5 stars$1.92+5.5%$21.00+993.8%+14.0%$53.82M$57.67M-0.86170Earnings ReportGap UpSABSSAB Biotherapeutics2.6877 of 5 stars$2.02-8.2%$11.00+444.6%-8.5%$22.90M$1.32M-0.51140BOLTBolt Biotherapeutics3.3951 of 5 stars$5.54-0.6%$50.00+803.0%-62.9%$10.68M$7.69M-0.1790News CoverageEarnings ReportAnalyst ForecastAMGNAmgen4.6617 of 5 stars$285.09-1.1%$303.76+6.5%-7.8%$155.17B$33.42B23.3128,000Positive NewsAnalyst RevisionGILDGilead Sciences4.8474 of 5 stars$120.47+0.9%$114.82-4.7%+60.4%$148.16B$28.75B24.0017,600Positive NewsAnalyst RevisionVRTXVertex Pharmaceuticals4.9454 of 5 stars$374.46+2.2%$497.10+32.8%-17.7%$93.98B$11.02B26.776,100Positive NewsREGNRegeneron Pharmaceuticals4.8397 of 5 stars$545.94-3.0%$826.91+51.5%-50.8%$59.67B$14.20B13.7615,106Positive NewsDividend AnnouncementAnalyst RevisionALNYAlnylam Pharmaceuticals4.2473 of 5 stars$435.00-0.9%$403.92-7.1%+67.4%$57.53B$2.25B-176.112,230Positive NewsInsider TradeBIIBBiogen4.8623 of 5 stars$128.00-2.0%$185.63+45.0%-31.4%$19.16B$9.68B12.247,605Positive NewsAnalyst Revision Related Companies and Tools Related Companies Dominari Competitors Fortress Biotech Competitors SAB Biotherapeutics Competitors Bolt Biotherapeutics Competitors Amgen Competitors Gilead Sciences Competitors Vertex Pharmaceuticals Competitors Regeneron Pharmaceuticals Competitors Alnylam Pharmaceuticals Competitors Biogen Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CRIS) was last updated on 8/18/2025 by MarketBeat.com Staff From Our Partners"AI Upgrade" Coming Sept. 1stA new “AI Upgrade” is rolling out on September 1st—and tech leaders are calling it transformational. Softbank’...Behind the Markets | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredNew law could create $3.7 trillion tsunami.During a meeting in Washington D.C., Jeff Brown discovered a bold initiative. He calls it “President Trump’...Brownstone Research | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredNational 'Stock Market Reset' Coming September 30 (New WH Order)Crash Coming Sept 30? Analysts Warn of New Crisis A new problem on the U.S. power grid is putting millions ...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Curis, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Curis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access